甲状腺乳头状癌组织c-erbB2、CyclinD1、Akt1蛋白表达研究  

Expression of c-erbB2,CyclinD1,and Akt1 proteins in papillary thyroid carcinoma tissue

作　　者：韩笑[1] 樊卫[2] 徐倩 贾栋舜 胡飞 杭程 Han Xiao;Fan Wei;Xu Qian;Jia Dongshun;Hu Fei;Hang Cheng(Department of Pathology,Huai'an Cancer Hospital,Huai'an 223200,China;Department of Laboratory Medicine,Huai'an Cancer Hospital,Huai'an 223200,China;Department of Clinical Laboratory,Lianshui People's Hospital of Kangda College Affiliated to Nanjing Medical University,Huai'an 223400,China;Department of Pathology,Huai'an Third People's Hospital,Huai'an 223200,China)

机构地区：[1]江苏省淮安市肿瘤医院病理科,淮安223200 [2]江苏省淮安市肿瘤医院检验科,淮安223200 [3]南京医科大学康达学院附属涟水人民医院检验科,淮安223400 [4]淮安市第三人民医院病理科,淮安223200

出　　处：《中华地方病学杂志》2024年第12期954-958,共5页Chinese Journal of Endemiology

基　　金：江苏省卫生健康委科研项目(Z2021044A)

摘　　要：目的探讨甲状腺乳头状癌组织人表皮生长因子受体2(c-erbB2)、细胞周期蛋白D1(CyclinD1)和蛋白激酶B1(Akt1)蛋白表达情况。方法采用回顾性研究,收集江苏省淮安市肿瘤医院2021年1月至2022年10月确诊为甲状腺乳头状癌患者(n=117)的甲状腺乳头状癌组织和癌旁组织、病理和病历资料以及1年随访情况,采用免疫组织化学法测定甲状腺组织c-erbB2、CyclinD1、Akt1蛋白表达情况;比较癌组织与癌旁组织以及不同临床特征、复发情况患者癌组织c-erbB2、CyclinD1、Akt1蛋白阳性率。结果甲状腺乳头状癌患者癌组织与癌旁组织c-erbB2[36.75%(43/117)比5.98%(7/117)]、CyclinD1[47.86%(56/117)比6.84%(8/117)]和Akt1蛋白阳性率[64.96%(76/117)比11.97%(14/117)]比较,差异均有统计学意义(χ^(2)=32.96、49.55、69.41,均P<0.001)。不同肿瘤-淋巴结-转移(TNM)分期、侵犯被膜和淋巴结转移情况患者癌组织c-erbB2、CyclinD1、Akt1蛋白阳性率比较,差异均有统计学意义(χ^(2)=40.67、20.47、12.07,13.68、7.25、9.16,22.04、27.18、46.31,均P<0.05);不同性别、年龄、吸烟史、饮酒史、肿瘤最大径以及是否肿瘤多灶性和伴桥本甲状腺炎患者癌组织c-erbB2、CyclinD1、Akt1蛋白阳性率比较,差异均无统计学意义(均P>0.05)。随访结果显示,117例甲状腺乳头状癌患者中,复发15例、无复发102例,复发组患者癌组织c-erbB2、CyclinD1、Akt1蛋白阳性率均高于无复发组(χ^(2)=4.00、4.47、6.09,均P<0.05)。结论甲状腺乳头状癌组织c-erbB2、CyclinD1和Akt1蛋白阳性率均较高,且与患者TNM分期、侵犯被膜、淋巴结转移和复发情况密切相关。Objective To investigate the protein expression of human epidermal growth factor receptor 2(c-erbB2),CyclinD1,and protein kinase B1(Akt1)in papillary thyroid carcinoma tissue.Methods A retrospective study was conducted to collect papillary thyroid carcinoma tissues,adjacent tissues,pathological and medical records,as well as one year follow-up data of patients(n=117)diagnosed with papillary thyroid carcinoma at Huai'an Cancer Hospital in Jiangsu Province from January 2021 to October 2022.The protein expression of c-erbB2,CyclinD1,and Akt1 were determined by immunohistochemistry.The positive rates of c-erbB2,CyclinD1,and Akt1 proteins in cancerous tissue and adjacent tissues,and cancerous tissue of patients with different clinical features and recurrence status were compared.Results There were statistically significant differences in the positive rates of c-erbB2[36.75%(43/117)vs 5.98%(7/117)],CyclinD1[47.86%(56/117)vs 6.84%(8/117)],and Akt1 proteins[64.96%(76/117)vs 11.97%(14/117)]between the cancerous tissue and adjacent tissue of patients with papillary thyroid carcinoma(χ^(2)=32.96,49.55,69.41,P<0.001).There were statistically significant differences in the positive rates of c-erbB2,CyclinD1,and Akt1 proteins in cancerous tissues of patients with different tumor node metastasis(TNM)classification staging,invasion of the capsule,and lymph node metastasis(χ^(2)=40.67,20.47,12.07,13.68,7.25,9.16,22.04,27.18,46.31,P<0.05).There was no statistically significant difference in the positive rates of c-erbB2,CyclinD1,and Akt1 proteins in cancerous tissues of patients with different genders,ages,smoking history,drinking history,maximum tumor diameter,and whether the tumor was multifocal or accompanied by Hashimoto's thyroiditis(P>0.05).The follow-up results of 117 patients with papillary thyroid carcinoma showed that there were 15 cases of recurrence and 102 cases of no recurrence.The positive rates of c-erbB2,CyclinD1,and Akt1 proteins in the cancerous tissue of the recurrence group were higher than those of the non

关 键 词：甲状腺乳头状癌 人表皮生长因子受体2 细胞周期蛋白D1 蛋白激酶B1 

分 类 号：R736.1[医药卫生—肿瘤]